-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33

Benzinga·12/16/2025 14:57:01
語音播報
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:KYTX) with a Overweight and raises the price target from $31 to $33.